Nantahala Capital Management LLC Takes Position in Disc Medicine, Inc. (NASDAQ:IRON)

Nantahala Capital Management LLC purchased a new stake in Disc Medicine, Inc. (NASDAQ:IRON) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 150,000 shares of the company’s stock, valued at approximately $6,760,000. Nantahala Capital Management LLC owned 0.61% of Disc Medicine as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Perceptive Advisors LLC raised its position in shares of Disc Medicine by 14.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company’s stock worth $59,091,000 after purchasing an additional 127,404 shares during the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of Disc Medicine by 19.8% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 785,000 shares of the company’s stock worth $45,342,000 after purchasing an additional 130,000 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in Disc Medicine in the 1st quarter valued at $7,429,000. Jennison Associates LLC raised its stake in Disc Medicine by 349.1% in the 1st quarter. Jennison Associates LLC now owns 193,240 shares of the company’s stock valued at $12,031,000 after purchasing an additional 150,209 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Disc Medicine by 59.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock valued at $58,788,000 after purchasing an additional 353,382 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Trading Down 1.9 %

Shares of NASDAQ:IRON opened at $49.14 on Tuesday. The business has a 50-day moving average price of $47.19 and a 200 day moving average price of $42.30. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -14.54 and a beta of 0.59.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.08. As a group, equities research analysts predict that Disc Medicine, Inc. will post -4.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IRON. Wells Fargo & Company initiated coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Disc Medicine in a research note on Friday, August 9th. BMO Capital Markets reissued an “outperform” rating and issued a $70.00 target price (up from $50.00) on shares of Disc Medicine in a research note on Monday, June 17th. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a report on Monday, September 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine currently has an average rating of “Moderate Buy” and an average price target of $64.13.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.